<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.

J Clin Oncol · 2025 · PMC12711279 · PMID 41223345

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendP = .07so close (0.05 < p ≤ 0.1)

The composite biomarker was prognostic for progression in the 177 Lu + SBRT group (time ratio [TR], 1.8 [95% CI, 1.21 to 2.66]; P = .0037; Fig 3 C) and showed a trend in the SBRT group (TR, 1.6 [95% CI, 0.96 to 2.66]; P = .07; Fig 3 D).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

&lt;sup&gt;177&lt;/sup&gt;Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.

The sentences

<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.